- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00365157
Eribulinmesylat til behandling af patienter med lokalt avanceret eller metastatisk kræft i urothelium og nyredysfunktion
En fase I/II undersøgelse af E7389 Halichondrin B Analog (NSC # 707389) i metastatisk urotelial kræft og nyreinsufficiens
This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue (locally advanced) or to other places in the body (metastatic)and kidney dysfunction. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy drugs may have different effects in patients who have changes in their kidney function.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To establish whether eribulin mesylate (E7389) can be given safely to patients with moderate and severe renal dysfunction at 1.4 mg/m^2/week (the maximum tolerated dose [MTD] previously defined for patients with normal renal function) on days 1 and 8 of a 21-day cycle. (Phase I) II. To characterize the pharmacokinetic (PK) profile of E7389 in patients with moderate and severe renal dysfunction. (Phase I) III. To determine the response rate of patients with advanced urothelial carcinomas to E7389 in the first-line setting. (Phase II) IV. To determine the 6-month, progression-free survival and overall survival of patients with advanced urothelial carcinomas treated with E7389. (Phase II) V. To document the toxicity associated with the administration of E7389 to patients with advanced urothelial carcinoma patients and varying degrees of renal dysfunction. (Phase II) VI. To determine the response rate of patients with advanced urothelial carcinomas to E7389 in the setting of progression after prior platinum-based chemotherapy for advanced or recurrent disease, in two cohorts: tubulin-inhibitor treated or tubulin-inhibitor naive. (tubulin inhibitors in common use for urothelial cancer include paclitaxel, docetaxel and vinblastine). (Phase II) (per Amendment 6) VII. To determine the 6-month progression-free survival and overall survival of patients with advanced urothelial carcinomas treated with E7389 after platinum-based therapy for recurrent or advanced disease. (Phase II) (per Amendment 6) VIII. To document the toxicity associated with the administration of E7389 to patients with advanced urothelial carcinoma patients in the second line and later setting. (Phase II) (per Amendment 6) IX. To compare men and women with advanced bladder cancer treated with E7389 with respect to toxicity of E7389 as classified by Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 for (i) all hematologic toxicities, (ii) all non- hematologic toxicities, and (iii) the most frequently observed toxicities (neutropenia, anemia, leucopenia, infection). (Enrollment to additional females) (per Amendment 11) X. To compare men and women with advanced bladder cancer treated with E7389 with respect to response to E7389 as evidenced by (i) disease control rate (DCR) defined as stable disease (SD)+partial response (PR)+complete response (CR) at 12 weeks, (ii) progression-free survival (PFS), and (iii) overall survival (OS). (Enrollment to additional females) (per Amendment 11) XI. To compare men and women with advanced bladder cancer treated with E7389 with respect to pharmacokinetics of E7389. (Enrollment to additional females) (per Amendment 11) XII. To compare men and women with advanced bladder cancer treated with E7389 with respect to tumoral expression of genes involved in the mechanism of action of E7389, including tubulin isotypes, microtubule-associated protein 4 (MAP4), and stathmin. (Enrollment to additional females) (per Amendment 11)
OUTLINE:
Patients receive eribulin mesylate intravenously (IV) over 1-2 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up monthly for 12 months and then every 3 months for up to 24 months.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
California
-
Beverly Hills, California, Forenede Stater, 90211
- Tower Cancer Research Foundation
-
Duarte, California, Forenede Stater, 91010
- City of Hope Comprehensive Cancer Center
-
Lancaster, California, Forenede Stater, 93534
- City of Hope Antelope Valley
-
Los Angeles, California, Forenede Stater, 90033
- USC / Norris Comprehensive Cancer Center
-
Martinez, California, Forenede Stater, 94553-3156
- Contra Costa Regional Medical Center
-
Martinez, California, Forenede Stater, 94553
- Veterans Administration Hospital - Martinez
-
Sacramento, California, Forenede Stater, 95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena, California, Forenede Stater, 91030
- City of Hope South Pasadena
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- University of Chicago Comprehensive Cancer Center
-
Decatur, Illinois, Forenede Stater, 62526
- Decatur Memorial Hospital
-
Evanston, Illinois, Forenede Stater, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Harvey, Illinois, Forenede Stater, 60426
- Ingalls Memorial Hospital
-
Joliet, Illinois, Forenede Stater, 60435
- Duly Health and Care Joliet
-
Maywood, Illinois, Forenede Stater, 60153
- Loyola University Medical Center
-
Peoria, Illinois, Forenede Stater, 61615
- Illinois CancerCare-Peoria
-
Springfield, Illinois, Forenede Stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forenede Stater, 62702
- Central Illinois Hematology Oncology Center
-
-
Indiana
-
Fort Wayne, Indiana, Forenede Stater, 46845
- Fort Wayne Medical Oncology and Hematology Inc-Parkview
-
Kokomo, Indiana, Forenede Stater, 46904
- Community Howard Regional Health
-
South Bend, Indiana, Forenede Stater, 46628
- Northern Indiana Cancer Research Consortium
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- University of Michigan Rogel Cancer Center
-
Detroit, Michigan, Forenede Stater, 48201
- Wayne State University/Karmanos Cancer Institute
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Oncology Care Associates PLLC
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63141
- Mercy Hospital Saint Louis
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- UPMC Hillman Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Medical College of Wisconsin
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients must have locally advanced or metastatic urothelial cancer that is not amenable to surgical treatment
- Patients must have histologically or cytologically confirmed urothelial tract carcinoma
- Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral computed tomography (CT) scan
- All patients may have received up to two prior lines of chemotherapy for recurrent/advanced disease
- Patients must have received at least one platinum-based chemotherapy for recurrent/advanced disease; recurrent disease is defined as having recurred after definitive therapy and advanced disease is defined as T4 and/or N2 and/or M1; in addition, for completion of Cohort #2, patients must also have received a tubulin inhibitor as part of their therapy for urothelial cancer; for purposes of this evaluation, treatment with chemotherapy regimens where carboplatin or similar is substituted for cisplatin or where a taxane is added or removed will be considered the same regimen; tubulin inhibitors in common use include paclitaxel, docetaxel, and vinblastine; the exception to this requirement applies to women
- Women with and without prior therapy are also eligible; priority will be given to those who consent to participating in the pharmacokinetic studies
- Life expectancy of greater than 6 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2 and Karnofsky >= 60%
- Absolute neutrophil count >= 1,000/mcL
- Platelets >= 100,000/mcL
- Hemoglobin >= 9 g/dL
- Total bilirubin =< 1.5 institutional upper limit of normal (IULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X IULN
- Patients must have either (a) normal kidney function (i.e. creatinine =< 1.5 X upper limit of normal [ULN] OR calculated creatinine clearance >= 60 mL/min by the modified Cockcroft and Gault Formula OR a creatinine clearance >= 60 mL/min obtained from a 24-hour urine collection) or (b) moderate or severe renal dysfunction (i.e. creatinine clearance < 60 mL/min and >= 20 mL/min)
- Patients with symptomatic uremia, uncontrolled edema or unstable serum electrolytes should not enter the trial until such time as they have been stabilized - such patients should be discussed with the principal investigator
- Eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of E7389 Halichondrin analog will be determined following review of their case by the principal investigator
- The effects of E7389 Halichondrin analog on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because tubulin inhibitors are known to be teratogenic, women and men of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Patients must have the ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients may not be receiving any other investigational agents
- Patients with brain metastasis that are unstable (i.e. presenting with neurologic symptoms that progress or require increasing doses of steroids within a 4-week period) or are untreated (i.e. not radiated) should be excluded
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because E7389 Halichondrin analog is tubulin inhibitor agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with E7389 Halichondrin analog, breastfeeding should be discontinued if the mother is treated with E7389
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with E7389 Halichondrin analog; HIV-positive patients with CD4+ =< 500/mm3 are ineligible because they are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in this group of patients when indicated
- Prior therapy with E7389 Halichondrin analog (eribulin)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Treatment (eribulin mesylate)
Patients receive eribulin mesylate IV over 1-2 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
Correlative studies Correlative studies Given IV
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum Tolerated Dose (MTD) of Eribulin Mesylate for Patients Who Have Received a Tubulin-inhibitor for the Recurrent/Advanced Disease (Phase I)
Tidsramme: 21 days
|
MTD will be graded according to Common Terminology Criteria for Adverse (CTCAE) version 5.0. |
21 days
|
|
MTD of Eribulin Mesylate for Patients Who Have Not Received a Tubulin-inhibitor for the Recurrent/Advanced Disease (Phase I)
Tidsramme: 21 days
|
MTD will be graded according to CTCAE version 5.0. |
21 days
|
|
Number of Subjects With Overall Response
Tidsramme: Up to 6 months
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): Complete Response (CR), Disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter (LD) of target lesions; Overall Response (OR) = CR + PR |
Up to 6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free Survival (Phase II)
Tidsramme: From the start of treatment on day 1 until progression, death, or the start of another treatment, assessed at 6 months
|
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.1), as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, and appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. |
From the start of treatment on day 1 until progression, death, or the start of another treatment, assessed at 6 months
|
|
Progression-free Survival (Phase II)
Tidsramme: From the start of treatment on day 1 until progression, death, or the start of another treatment, assessed up to 12 months
|
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECISTv1.1), as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, and appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. |
From the start of treatment on day 1 until progression, death, or the start of another treatment, assessed up to 12 months
|
|
Overall Survival (Phase II)
Tidsramme: From the start of treatment on day 1 until death, assessed up to 12 months
|
Overall survival will be summarized as time from the start of treatment until death from any cause. |
From the start of treatment on day 1 until death, assessed up to 12 months
|
|
Number of Participants With Adverse Events (AE)
Tidsramme: Up to 24 months, or until the patient dies or refuses further follow up.
|
Graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. All observed toxicities (excluding unrelated or unlikely related AEs) will be summarized from the start of treatment until the end of treatment visit up to 24 months, or until the patient dies or refuses further follow up. |
Up to 24 months, or until the patient dies or refuses further follow up.
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacokinetic Parameters for Eribulin Mesylate
Tidsramme: At baseline; at 5, 10, 15, and 30 minutes; and at 1, 2, 4, 6, 8, 12, and 24 hours on day 1 of course 1 and at end of days 2-4 and 8 of course 1
|
Analyzed using compartmental and non-compartmental models. max concentration, systemic clearance, renal clearance, volume of distribution, half life, and area under the curve tabulated overall, and by prior exposure to tubulin-inhibitors, with summary statistics (means and standard deviations, or medians and ranges) and displayed with box-plots; the relationship between the PK parameters and indices of renal function (e.g. serum creatinine and creatinine clearance) will be examined using scatterplots and correlations. |
At baseline; at 5, 10, 15, and 30 minutes; and at 1, 2, 4, 6, 8, 12, and 24 hours on day 1 of course 1 and at end of days 2-4 and 8 of course 1
|
|
Expression Levels of the Tubulin Isotypes
Tidsramme: Baseline
|
For each of the tubulin isotypes, the distribution of the expression levels will be summarized with plots and standard statistical summary numbers; prior to analysis, the expression levels may be transformed to render the distributions more compatible with the assumptions of normal distribution. The association between the expression levels and response will be summarized with means and standard deviations and confidence intervals (or medians and ranges) and displayed with box-plots. |
Baseline
|
|
Disease Control Rate (Complete Response [CR] + Partial Response [PR] + Stable Disease [SD])
Tidsramme: 12 weeks
|
Logistic regression will be used to compare males and females, adjusting for the PK variables as well as age, renal status, and prior therapy. |
12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: David I Quinn, City of Hope Medical Center
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- NCI-2009-00170
- N01CM62201 (U.S. NIH-bevilling/kontrakt)
- P30CA033572 (U.S. NIH-bevilling/kontrakt)
- N01CM62209 (U.S. NIH-bevilling/kontrakt)
- U01CA062505 (U.S. NIH-bevilling/kontrakt)
- N01CM00071 (U.S. NIH-bevilling/kontrakt)
- UM1CA186717 (U.S. NIH-bevilling/kontrakt)
- N01CM00038 (U.S. NIH-bevilling/kontrakt)
- UM1CA186705 (U.S. NIH-bevilling/kontrakt)
- NCI-2009-00170 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- CDR0000492014
- PHII-75
- 7435 (Anden identifikator: CTEP)
- 7435 (Anden identifikator: City of Hope Comprehensive Cancer Center)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .